RARECYTE INC.

In News

RareCyte showcases clinical-scale spatial proteomics portfolio at AACR 2026 - Select Science

Select Science - Apr 21, 2026

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment - BioSpace

BioSpace - Apr 20, 2026

RareCyte secures $20M financing to expand the Orion™ Spatial Biology platform including Multiplex Assay Reagents, Software and Precision Biology Services - PR Newswire

PR Newswire - Jun 27, 2024

New test might expand ability to find tumor cells in blood - UW Medicine | Newsroom

UW Medicine | Newsroom - Jun 21, 2023

High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers - Nature

Nature - Jun 22, 2023

Liquid biopsy startup RareCyte announces $30M round and new CEO to fuel rare cell detection - GeekWire

GeekWire - Aug 29, 2017

Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens - Wiley & Sons

Wiley & Sons - Jun 25, 2021

Open source software for multiplex staining & image analysis - Select Science

Select Science - Oct 23, 2024

Gastrointestinal Research Foundation to fund programs targeting digestive cancers - BioWorld News

BioWorld News - Nov 04, 2022

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer | Oncogene - Nature

Nature - Sep 21, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment